Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review - Summary - MDSpire

Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review

  • By

  • Dario S. Lopez Delgado

  • Miriam Gabriela Reyes-Zermeño

  • Elian David Sanjuanelo Lemus

  • Catherine G. Acosta-Celis

  • María Amparo Kantún-Marín

  • Martín Gomez-Lujan

  • Kevin Gabriel Fallaza-Moya

  • Oscar Muñoz-Chuquilín

  • Sandra Trujillo-Levano

  • Giancarlo Gutierrez-Chavez

  • Cesar Bonilla-Asalde

  • Oriana Rivera-Lozada

  • Joshuan J. Barboza

  • July 6, 2026

  • 0 min

Share

Objective:

To synthesize evidence on phenotypic and genomic determinants of variability in pharmacotherapy response and propose a pragmatic framework for precision pharmacotherapy in obesity.

Approach:
  • Review Design: Narrative review integrating data from randomized trials, post-hoc subgroup analyses, observational cohorts, neurobehavioral studies, pharmacogenomic investigations, and polygenic risk score research.
Key Findings:
  • Response heterogeneity in obesity pharmacotherapy is influenced by factors such as central satiety circuitry, metabolic status, sex, baseline adiposity, treatment indication, previous GLP-1RA exposure, adherence, and tolerability.
  • Early on-treatment weight change, usually assessed within 12–16 weeks, is a clinically actionable predictor of longer-term outcomes.
  • Phenotype-guided approaches can classify mechanisms affecting weight loss, such as impaired satiation, postprandial hunger, emotional or hedonic eating, and low energy expenditure, aiding in medication selection.
  • Emerging genomic signals are promising but not yet ready for routine clinical application.
Interpretation:

Precision pharmacotherapy in obesity is currently best achieved through phenotype-guided treatment, structured early-response monitoring, and proactive management of adherence and tolerability, with genomic tools requiring further validation.

Limitations:
  • Existing genomic tools are investigational and lack sufficient replication for clinical use.
  • Current treatment algorithms primarily rely on BMI and comorbidities rather than systematic phenotypic classification.
Conclusion:

A structured approach to obesity pharmacotherapy that incorporates phenotypic and genomic data is essential for improving treatment outcomes.

Original Source(s)

Related Content